Kazia Therapeutics Secures $2 Million in Premium Private Placement to Advance Cancer Drug Development

Reuters
01 Aug
<a href="https://laohu8.com/S/KZA.AU">Kazia Therapeutics</a> Secures $2 Million in Premium Private Placement to Advance Cancer Drug Development

Kazia Therapeutics Limited, a company focused on oncology drug development, announced a $2 million private placement with institutional investors. The transaction involves the sale of ordinary shares and pre-funded warrants at a 5% premium to the recent closing price. The funds will support the ongoing clinical development of Kazia's lead programs, including paxalisib and EVT801, as well as general corporate purposes. The transaction is set to close soon, pending customary conditions. Kazia plans to file a shelf registration statement with the SEC to register the resale of certain securities. CEO Dr. John Friend expressed gratitude for investor support and anticipation for upcoming clinical data releases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42432) on August 01, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10